D Terrence Foster, MD
Interventional Pain Medicine · Stockbridge, GANPI 1013900976
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Pfizer at 30.3% of the total. Reporting peaked in 2019 at $125 and has fallen 87.5% since, to $16 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in GA, where the typical reported total is $4,377.
Across 10 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$59
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$46
- Boston Scientific$40
- Exact Sciences$22
- Valinor Pharma, LLC$16
- Fidia Pharma USA Inc.$13
Across 6 payments — averaging $50,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$297K
- Endo Pharmaceuticals Inc.$8K
What the payments were for
- Food & beverage$196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $46 |
| Boston Scientific | 2 | $40 |
| Exact Sciences | 1 | $22 |
| Valinor Pharma, LLC | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $13 |
How this compares
$196 in reported general payments places this provider in the 5th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 945 | $26,023 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 572 | $14,564 |
| MovantikNaloxegol Oxalate | 34 | $14,294 |
| LinzessLinaclotide | 14 | $9,373 |
| Diclofenac Epolamine | 14 | $8,686 |
| Pregabalin | 438 | $8,471 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $8,265 |
| Buprenorphine | 36 | $8,190 |
| Gabapentin | 970 | $7,966 |
| Lidocaine | 83 | $7,272 |
| Tizanidine Hcl | 640 | $6,508 |
| Hysingla ErHydrocodone Bitartrate | 12 | $6,235 |
| ButransBuprenorphine | 18 | $5,892 |
| Diclofenac Sodium | 194 | $3,849 |
| Oxycodone Hcl | 163 | $2,814 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Stockbridge
- Christopher AndrianoStockbridge$41K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Guensley DelvaWaycross$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.